Directory
>
Frank Fang
Frank Fang
Deputy President & Head Of Precision Chemistry – G2D2 | Eisai US
Boston, Massachusetts, United States
Frank Fang
Summary
Frank Fang is a distinguished chemist and leader in the pharmaceutical industry, currently serving as the Deputy President and Head of Precision Chemistry at Eisai's Center for Genetics Guided Dementia Discovery (G2D2). With a strong foundation in organic chemistry, he has co-founded an interdisciplinary team focused on addressing unmet medical needs through innovative drug development. His notable achievements include the commercialization of Halaven and the discovery of E7766, showcasing his commitment to patient-centered scientific discovery. Frank holds an impressive portfolio of 56 US patents and has co-authored 33 scientific publications, reflecting his significant contributions to the field. He is also actively involved in community service, volunteering with his therapy dog, Tony. His educational background includes a PhD from Yale University and a postdoctoral fellowship at Harvard, underscoring his academic excellence. Frank's leadership experience, combined with his technical expertise, positions him as a key figure in advancing pharmaceutical science.
Frank Fang
Work Experience
Deputy President & Head Of Precision Chemistry – G2D2 at
Eisai US
January 2019 - Present
Deputy President And Head, Integrated Chemistry, Andover Innovative Medicines at
Eisai
January 2015 - January 2019
Frank Fang
Education
University of Massachusetts Amherst, Bachelor's Degree
Yale University, Doctor Of Philosophy - Phd
Harvard University, Nih Postdoctoral Fellow
Frequently Asked Questions about Frank Fang
What is Frank Fang email address?
Frank Fang's primary email address is **********@eisai.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Frank Fang work for?
Frank Fang is a Deputy President & Head Of Precision Chemistry – G2D2 at Eisai US, a company specializing in Biological products, except diagnostic.
Where Frank Fang graduated from?
Frank Fang holds a degree in Chemistry from University of Massachusetts Amherst.
How can I directly contact Frank Fang?
To contact Frank Fang directly, you can use the email address **********@eisai.com. Complete contact information is available upon registration with Muraena.
Who is Frank Fang?
Frank Fang is a distinguished chemist and leader in the pharmaceutical industry, currently serving as the Deputy President and Head of Precision Chemistry at Eisai's Center for Genetics Guided Dementia Discovery (G2D2). With a strong foundation in organic chemistry, he has co-founded an interdisciplinary team focused on addressing unmet medical needs through innovative drug development. His notable achievements include the commercialization of Halaven and the discovery of E7766, showcasing his commitment to patient-centered scientific discovery. Frank holds an impressive portfolio of 56 US patents and has co-authored 33 scientific publications, reflecting his significant contributions to the field. He is also actively involved in community service, volunteering with his therapy dog, Tony. His educational background includes a PhD from Yale University and a postdoctoral fellowship at Harvard, underscoring his academic excellence. Frank's leadership experience, combined with his technical expertise, positions him as a key figure in advancing pharmaceutical science.
Frank`s contact details
**********@eisai.com
Colleagues
Executive Director
President, Partnership Management Core Functional Unit
Executive Vice President, Purpose & Chief Business Officer
Chief Administrative Officer & Executive Vice President - Integrity
Executive Director. International Product Safety
Executive Director, US Payer Markets (Neurology and Oncology)
Executive Director, Statistical Programming, DHBL-CEG
Chief Medical Officer, Senior Vice President, Head of Global Medical Affairs, Neurology
Executive Director, External Stakeholder Engagement, Ad, Global Medical Affairs, Nbg At Eisai Us
Executive Director, Regulatory Strategy - Oncology